Takeda Pharmaceutical (NYSE:TAK) Insider Ramy Riad Ahmed Ibrahim Sells 7,277 Shares of Stock

Takeda Pharmaceutical Co. (NYSE:TAK) insider Ramy Riad Ahmed Ibrahim sold 7,277 shares of the firm’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $17.10, for a total value of $124,436.70. Following the sale, the insider directly owned 102,588 shares in the company, valued at approximately $1,754,254.80. This represents a 6.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Takeda Pharmaceutical Stock Down 0.3%

NYSE TAK opened at $17.42 on Thursday. Takeda Pharmaceutical Co. has a 12 month low of $12.99 and a 12 month high of $18.90. The company has a current ratio of 1.14, a quick ratio of 0.62 and a debt-to-equity ratio of 0.58. The stock has a market cap of $55.82 billion, a PE ratio of 51.24 and a beta of -0.08. The stock’s 50 day moving average is $16.49 and its 200 day moving average is $17.13.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings data on Tuesday, March 31st. The company reported $0.56 earnings per share for the quarter. Takeda Pharmaceutical had a return on equity of 10.95% and a net margin of 3.80%.The firm had revenue of $6.90 billion during the quarter. Research analysts predict that Takeda Pharmaceutical Co. will post 3.01 EPS for the current fiscal year.

Trending Headlines about Takeda Pharmaceutical

Here are the key news stories impacting Takeda Pharmaceutical this week:

• Positive Sentiment: Insiders continued to hold substantial positions after the transactions, suggesting the sales do not necessarily reflect a loss of confidence in Takeda’s business or outlook. The filings state that the shares were sold to cover tax withholding obligations related to vested equity awards. SEC insider filing
• Neutral Sentiment: Analyst sentiment remains mixed: ratings include two Buys, one Hold and one Sell, resulting in an overall “Hold” consensus. Recent institutional buying has also provided some support, but those purchases were relatively small compared with Takeda’s market capitalization. Takeda stock analysis
• Negative Sentiment: Multiple senior executives and insiders sold a combined 399,? shares at an average price of $17.10. CEO Julie So-Young Kim sold 89,090 shares, Andrew Stewart Plump sold 165,393 shares and General Counsel Natalie Anne Marie Furney sold 30,868 shares. Other insiders also reduced their holdings by approximately 5.9% to 17.8%, which could weigh on investor sentiment despite the tax-related explanation. Takeda insider sales report

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Capital Research Global Investors raised its position in Takeda Pharmaceutical by 0.6% during the 4th quarter. Capital Research Global Investors now owns 13,486,772 shares of the company’s stock valued at $210,259,000 after purchasing an additional 82,643 shares in the last quarter. UBS Group AG increased its stake in shares of Takeda Pharmaceutical by 46.4% during the third quarter. UBS Group AG now owns 5,893,969 shares of the company’s stock valued at $86,288,000 after buying an additional 1,869,323 shares during the period. Arrowstreet Capital Limited Partnership increased its stake in shares of Takeda Pharmaceutical by 100.9% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 5,682,847 shares of the company’s stock valued at $88,596,000 after buying an additional 2,854,069 shares during the period. Goldman Sachs Group Inc. raised its holdings in shares of Takeda Pharmaceutical by 15.0% in the first quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company’s stock valued at $79,120,000 after acquiring an additional 692,404 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its stake in Takeda Pharmaceutical by 14.2% in the first quarter. Renaissance Technologies LLC now owns 2,989,100 shares of the company’s stock worth $55,358,000 after acquiring an additional 370,800 shares during the period. Institutional investors own 9.17% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on TAK. Zacks Research upgraded Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 4th. Weiss Ratings lowered Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, July 30th. Finally, Wall Street Zen upgraded Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Saturday, July 18th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold”.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.